For the quarter ending 2025-09-30, AUPH had $20,187K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 31,551 | 44,857 |
| Share-based compensation | 5,919 | 2,031 |
| Amortization and depreciation | 4,865 | 9,720 |
| Foreign exchange loss (gain) on revaluation of monoplant finance lease liability | -53 | -9,265 |
| Net amortization of premiums and discounts on investments | 2,625 | 5,219 |
| Other, net | -720 | -4,132 |
| Accounts receivable, net | -9,363 | 3,547 |
| Inventory, net | -1,710 | 7,275 |
| Prepaid expenses and other current assets | 4,166 | -5,106 |
| Other noncurrent operating assets | 0 | -730 |
| Accounts payable | -1,098 | -1,875 |
| Accrued expenses and other liabilities | -641 | -17,136 |
| Deferred revenue | -997 | 5,147 |
| Lease liabilities | -205 | -395 |
| Cash flows from operating activities | 44,449 | 45,541 |
| Proceeds from the sale and maturities of investments | 93,500 | 255,285 |
| Purchases of investments | 107,207 | 237,411 |
| Purchases of property, equipment and intangible assets | 65 | 115 |
| Upfront lease payment | 0 | - |
| Cash flows from investing activities | -13,772 | 17,759 |
| Repurchase of common shares | 8,671 | 89,485 |
| Principal portion of finance lease payments | 3,448 | 6,201 |
| Proceeds from issuance of common shares from exercise of stock options and vesting of rsus and performance awards | 1,993 | 10,590 |
| Proceeds from issuance of common shares under espp | 0 | 401 |
| Taxes paid related to net settlement of exercises of stock options and vesting of rsus and performance awards | 364 | 9,036 |
| Cash flows from financing activities | -10,490 | -93,731 |
| Net decrease in cash, cash equivalents and restricted cash | 20,187 | -30,431 |
| Cash and cash equivalents at beginning of period | 83,433 | - |
| Cash and cash equivalents at end of period | 73,189 | - |
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)